Device Trial Radar · NCT03113955
STOPPER CHINA:With Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma
Last checked: Nov 21, 2026Latest source record: Dec 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
109
Actual
Start
Oct 24, 2017
Primary completion
Jun 28, 2019
Study completion Feb 28, 2020
Sponsor
- Lead sponsor
- Varian Medical SystemsNot on our public-company list
- Sponsor type
- Industry
- First posted
- Apr 14, 2017
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Single-arm Trial of Transcatheter Arterial Chemoembolization with Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma
Conditions
- Localized Hepatocellular Carcinoma
Interventions
Tandem Microsphere loaded with EpirubicinDevice
The primary objective of this study is to evaluate the safety and efficacy of transcatheter arterial chemoembolization with Tandem Microspheres loaded with Epirubicin in the treatment of patients with localized hepatocellular carcinoma (HCC)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Objective Tumor Response at 6 Months by MRI (Magnetic Resonance Imaging)Time frame: At 6 months
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
9 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.